125 related articles for article (PubMed ID: 26601425)
1. Risk factors for developing infusion reaction after rituximab administration in patients with B-cell non-Hodgkin's lymphoma.
Tachi T; Yasuda M; Usui K; Umeda M; Nagaya K; Osawa T; Ichihashi A; Noguchi Y; Goto H; Kasahara S; Takahashi T; Goto C; Teramachi H
Pharmazie; 2015 Oct; 70(10):674-7. PubMed ID: 26601425
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of factors influencing the occurrence of infusion reaction after initial treatment with rituximab].
Yasuda M; Tachi T; Umeda M; Usui K; Nagaya K; Osawa T; Ichihashi A; Goto H; Kasahara S; Takahashi T; Teramachi H; Goto C
Gan To Kagaku Ryoho; 2014 Aug; 41(8):975-9. PubMed ID: 25132029
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma.
Arai Y; Yamashita K; Mizugishi K; Nishikori M; Hishizawa M; Kondo T; Kitano T; Kawabata H; Kadowaki N; Takaori-Kondo A
Hematology; 2015 May; 20(4):196-202. PubMed ID: 25130775
[TBL] [Abstract][Full Text] [Related]
4. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia.
Meinhardt A; Burkhardt B; Zimmermann M; Borkhardt A; Kontny U; Klingebiel T; Berthold F; Janka-Schaub G; Klein C; Kabickova E; Klapper W; Attarbaschi A; Schrappe M; Reiter A;
J Clin Oncol; 2010 Jul; 28(19):3115-21. PubMed ID: 20516455
[TBL] [Abstract][Full Text] [Related]
5. Rituximab Faster Infusion for Patients With Non-Hodgkin's Lymphoma in the United States: Implications for Nursing Practice.
Dawson K
J Infus Nurs; 2015; 38 Suppl 6():S4-S10. PubMed ID: 26536411
[TBL] [Abstract][Full Text] [Related]
6. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
7. Rapid infusion rituximab changing practice for patient care.
Al Zahrani A; Ibrahim N; Al Eid A
J Oncol Pharm Pract; 2009 Sep; 15(3):183-6. PubMed ID: 19171551
[TBL] [Abstract][Full Text] [Related]
8. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
Leonard JP; Coleman M; Ketas J; Ashe M; Fiore JM; Furman RR; Niesvizky R; Shore T; Chadburn A; Horne H; Kovacs J; Ding CL; Wegener WA; Horak ID; Goldenberg DM
J Clin Oncol; 2005 Aug; 23(22):5044-51. PubMed ID: 15955901
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic options in patients with lymphoma and severe liver dysfunction.
Ghobrial IM; Wolf RC; Pereira DL; Fonseca R; White WL; Colgan JP; Habermann TM; Inwards DJ; Markovic SN; Ansell SM; Micallef IN; Porrata LF; Witzig TE
Mayo Clin Proc; 2004 Feb; 79(2):169-75. PubMed ID: 14959910
[TBL] [Abstract][Full Text] [Related]
11. A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas.
Zhang L; Fang Y; Kopeček J; Yang J
Eur J Pharm Sci; 2017 May; 103():36-46. PubMed ID: 28249824
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients.
Ansell SM; Geyer SM; Maurer MJ; Kurtin PJ; Micallef IN; Stella P; Etzell P; Novak AJ; Erlichman C; Witzig TE
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6056-63. PubMed ID: 17062681
[TBL] [Abstract][Full Text] [Related]
13. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
15. A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas.
Hayama T; Miura K; Uchiike A; Nakagawa M; Tsutsumi D; Sakagami M; Yoshida Y; Takei M
Int J Clin Pharm; 2017 Apr; 39(2):380-385. PubMed ID: 28144804
[TBL] [Abstract][Full Text] [Related]
16. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
Leonard JP; Coleman M; Ketas JC; Chadburn A; Furman R; Schuster MW; Feldman EJ; Ashe M; Schuster SJ; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Fields SZ; Cesano A; Goldenberg DM
Clin Cancer Res; 2004 Aug; 10(16):5327-34. PubMed ID: 15328168
[TBL] [Abstract][Full Text] [Related]
17. Peri-infusional adverse reactions to rituximab in patients with non-Hodgkin's lymphoma.
Arredondo-Garza T; Majluf-Cruz A; Vela-Ojeda J; Mariscal-Ramírez I; Solis-Anaya L; Lopez-Gutiérrez JR; Guadarrama CH; Rico-Curiel E; Armenta-San Sebastián JA; Castañeda-Hernández G
Arch Med Res; 2013 Oct; 44(7):549-54. PubMed ID: 24120421
[TBL] [Abstract][Full Text] [Related]
18. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
[TBL] [Abstract][Full Text] [Related]
19. Rituximab: a new monoclonal antibody therapy for non-Hodgkin's lymphoma.
Kosits C; Callaghan M
Oncol Nurs Forum; 2000; 27(1):51-9. PubMed ID: 10660923
[TBL] [Abstract][Full Text] [Related]
20. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
